<?xml version="1.0" encoding="UTF-8"?>
<p id="par0020">The urgency of antimicrobial resistance is specifically addressed in two opinion papers in the Special issue. Hu et al. describe the increasing awareness of the UK government about the AMR problem. According to the former UK Chief Medical Officer Professor Dame Sally Davies “antimicrobial resistance poses a catastrophic threat”. The UK government made AMR a priority, announced in their disease strategy 2020–2025 that the UK will become a world player in countering AMR, and allocated 32 million pounds for research in 2018 (Hu et al. 
 <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.eujim.2020.101136" id="intr0005" xmlns:xlink="http://www.w3.org/1999/xlink">https://doi.org/10.1016/j.eujim.2020.101136</ext-link>). Young and Craig (
 <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.eujim.2020.101072" id="intr0010" xmlns:xlink="http://www.w3.org/1999/xlink">https://doi.org/10.1016/j.eujim.2020.101072</ext-link>) discuss the urgency of antimicrobial resistant tuberculosis, which accounts for a third of deaths due to AMR and is the only antimicrobial resistant pathogen infectious through inhalation known so far. The authors discuss preliminary research about the possibilities of a Japanese traditional moxibustion treatment especially for people with latent tuberculosis.
</p>
